VIP (Vasoactive Intestinal Peptide)
VIP is a neuropeptide studied for its broad regulatory role in immune signaling, vasodilation pathways, and neuro-inflammatory communication. Within research environments, VIP is evaluated for its influence on cytokine balance, smooth muscle activity, and mucosal barrier dynamics.
As an endogenous signaling peptide, VIP interacts with VPAC receptors, making it a subject of interest in immune-modulatory and inflammatory pathway research models.
Compound Profile
Research Name: Vasoactive Intestinal Peptide
Alias: VIP
Category: Neuroimmune regulatory peptide
Primary Research Focus: Immune modulation, inflammatory signaling, vasodilation pathways
Format: Lyophilized powder
Reconstitution & Concentration
Upon reconstitution with an appropriate volume of bacteriostatic water, final concentration will vary depending on total diluent added. Researchers calculate concentration using the standard formula:
Total mg in vial ÷ Total mL added = mg per mL
For U-100 insulin syringes:
1 mL = 100 units
Units required are determined by dividing the desired mg amount by the final mg/mL concentration.
Research Applications
VIP is studied for its potential influence on:
Immune & Cytokine Regulation
-
Th1/Th2 balance modeling
-
Cytokine signaling modulation
-
Mast cell activity research
Neuro-Inflammatory Pathways
-
Neuroimmune communication
-
Microglial signaling dynamics
-
Central inflammatory response evaluation
Vascular & Smooth Muscle Activity
-
Vasodilation response modeling
-
Airway smooth muscle signaling
-
Gastrointestinal motility pathways
Barrier & Mucosal Integrity
-
Intestinal permeability research
-
Respiratory mucosal function studies
Its receptor-mediated signaling differentiates VIP from structural or regenerative peptides, placing it within neuroimmune regulatory research frameworks.
Monitoring Considerations
Within controlled research environments, investigators may observe:
Dose-dependent variables
-
Flushing due to vasodilatory activity
-
Blood pressure variability within models
-
Transient headache
Immune-related observations
-
Cytokine marker fluctuations
-
Changes in inflammatory signaling parameters
Less frequent observations
-
Mild gastrointestinal discomfort
-
Injection-site irritation
-
Lightheadedness
Monitoring is typically structured carefully due to VIP’s systemic receptor activity and vasodilatory properties.
Protocol Framework (Research Context)
Administration Frequency: Varies by study design
Common Study Duration: 4–12 weeks
Titration Strategy: Gradual incremental adjustments to evaluate tolerance and signaling response
Researchers often exercise caution when combining VIP with other immune-modulating or vasodilatory compounds to avoid overlapping pathway amplification.
Storage & Handling
Store lyophilized vial in a cool, dry environment.
Refrigerate after reconstitution.
Maintain sterile laboratory handling procedures at all times.
